Description: Tuoxin Pharmaceutical Group Co.,Ltd. engages in the research, development, production, and sale of chemical synthesis, biological fermentation nucleoside (acid) APIs, and pharmaceutical intermediates in China and internationally. It offers purine base, pyrimidine base, nucleosides, nucleotide, deoxynucleosides, dehyfrated nucleoside, 2'-modified, Cybinucleoside, and sugar series, and Azvudine intermediate. The company also provides Disodium 5'-cytidylate, Disodium 5'-uridylate, 5'-Adenosine monophosphate, and D-ribose, as well as citicoline sodium, ribavir Lin, inosine, acyclovir, cytosine, 5-fluorocytosine, cytidine, and other APIs and pharmaceutical intermediates. The company was founded in 2001 and is based in Xinxiang, China.
Home Page: www.tuoxinpharm.com
No. 515, Kelong Avenue
Xinxiang,
453000
China
Phone:
86 37 3635 1918
Officers
| Name | Title |
|---|---|
| Mr. Shaohua Yang | GM & Non-Independent Director |
| Ms. Huijuan Jiao | Chief Financial Officer |
| Mr. Xiuqiang Wang | Deputy GM & Director |
| Ms. Yuhua Yang | Board Secretary |
| Mr. Tao Li | Deputy General Manager |
Exchange: SHE
Country: CN : China
Currency: Renminbi (¥)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.7648 |
| Price-to-Sales TTM: | 10.0745 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1550 |